Lianjun Shen

机构：Innovacell Biotechnologie (Austria), AstraZeneca (Poland)

发表论文 75 篇 · 总被引 4111 次 · h-index 21

代表论文

• Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study (2022 · Blood Cancer Journal · 被引 109)
• CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies (2023 · Leukemia · 被引 40)
• Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). (2023 · Journal of Clinical Oncology · 被引 36)
• Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial (2023 · EClinicalMedicine · 被引 30)
• B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma (2024 · JAMA Oncology · 被引 27)
• Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma (2023 · Blood · 被引 21)